StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

Stopped early · Phase 1/Phase 2

Conditions studied: Full Thickness Thermal Burn

In brief

Autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. Autografting is the usual treatment for full-thickness (FT) burns. It works to close the wound, but can cause other problems: * Donor sites are painful, can become infected or scarred, or can even become FT wounds themselves * Treatment problems can require more grafting * Additional surgery increases risk of medical problems caused by the treatment Stratatech is trying to find a safe and effective treatment option for severe burns that uses less donor skin. All participants in this study received meshed autograft on one part of their burn (AG Tx). They received more widely meshed than AG Tx site autograft with a StrataGraft covering (SOMA Tx) on a different part of their burn.

Key facts

Study ID

NCT04765202

Run by

Stratatech, a Mallinckrodt Company

People needed

13

Starts

2021-10-10

Expected to finish

2024-06-07

Last updated by the study team

2025-05-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has 2% to 49% (inclusive) total body surface area (TBSA) thermal burn area, including areas of full thickness (FT) injury clinically indicated for surgical excision and autografting, appropriate for protocol-defined treatment areas
• Meets protocol-specified criteria for qualification and contraception
• Is willing and able to comply with all study procedures and requirements
• Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures

You may not qualify if…

• Is a prisoner, pregnant, or had previous autografting to treatment sites
• Is expected to survive less than 3 months
• Is participating in another interventional trial, or did within 30 days before enrollment
• Has anticipated treatment sites that are outside protocol-specified parameters
• Has concurrent clinically significant inhalation injury, inadequate fluid resuscitation, or burns of chemical or electrical (non-thermal) etiology
• Has other signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
• The safety or well-being of the participant
• The study objectives

Where it is running

• Medstar Washington Hospital Center — Washington D.C., District of Columbia, United States
• Tampa General Hospital / University of South Florida — Tampa, Florida, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• Stony Brook University — Stony Brook, New York, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.